Default company panoramic image
F0377bf3 871f 49fd 827a 01720320ba04

iVeena, LLC

Moran Eye Institute spin-out company providing intraocular drug delivery platform to treat major eye diseases.

  • Stage Concept Only
  • Industry Not Set
  • Location Salt Lake City, UT, USA
  • Currency USD

Company Summary

iVeena, LLC. is developing novel drug delivery solutions for treatment of common eye diseases that lead to blindness. These devices will increase patient comfort, compliance, and convenience and at the same time increase drug performance with improved sustained delivery.
iVeena will move its solutions into the market via a number of strategic channel partnerships each focused on specific drug-device combinations.

Team

  • Default avatar
    Dr. Greg M. Jones, MBA, PhD
    CEO

    Greg Jones, MBA, PhD was trained in physics (BS), business administration (MBA) and biomedi-cal science (PhD) and is currently the Associate Director of the Scientific Computing and Imaging (SCI) Institute. In 2000 Dr. Jones, along with several partners, founded Visual Influence, Inc. a SCI Institute spin-out. This center was incorporated as RayScale, Inc. which in 2008 sold to Nvidia, Inc.

  • Default avatar
    Dr. Balamurali K. Ambati, MD, PhD
    Founder/Chief Medical Officer

    Dr. Ambati is experienced in angiogenesis and animal models of eye disease, and has a strong basic science program in the mechanisms of and drug development for ocular angiogenic disorders. Dr. Ambati received his ophthalmology training at Harvard and Duke and has more than 10 years of clinical and research experience. He has published over 40 peer-reviewed publications and 2 books.

    Dr. Ambati practices at the Moran Eye Institute.